News
XTNT
0.4491
+2.07%
0.0091
Weekly Report: what happened at XTNT last week (0608-0612)?
Weekly Report · 1d ago
Weekly Report: what happened at XTNT last week (0601-0605)?
Weekly Report · 06/08 09:51
Weekly Report: what happened at XTNT last week (0525-0529)?
Weekly Report · 06/01 09:54
Weekly Report: what happened at XTNT last week (0518-0522)?
Weekly Report · 05/25 09:56
Xtant Medical Balances New Growth Bets With Near-Term Pain
TipRanks · 05/20 05:30
Weekly Report: what happened at XTNT last week (0511-0515)?
Weekly Report · 05/18 09:56
Xtant Medical Q1 Earnings Call Highlights
Barchart · 05/15 21:05
Maxim Group Sticks to Their Buy Rating for Xtant Medical Holdings (XTNT)
TipRanks · 05/14 13:18
Xtant Medical’s HEMOBLAST Deal with Dilon: High Sales Spend, Single‑Supplier Dependence and Termination Risk Threaten Returns
TipRanks · 05/14 06:03
Xtant Medical Boosts 2026 Outlook Amid Tough Quarter
TipRanks · 05/14 00:28
Xtant Medical raises FY 2026 revenue guidance to $101M-$105M as it adds HEMOBLAST distribution rights
Seeking Alpha · 05/13 20:21
Xtant Medical Holdings Price Target Maintained With a $1.00/Share by BTIG
Dow Jones · 05/13 18:22
BTIG Reiterates Buy on Xtant Medical Holdings, Maintains $1 Price Target
Benzinga · 05/13 18:12
Xtant Medical Hldgs Q1 2026 Earnings Call Transcript
Benzinga · 05/13 13:50
Xtant Medical reports Q1 EPS (2c) vs. 0c last year
TipRanks · 05/13 13:25
Xtant Medical raises FY26 revenue view to $101M-$105M from $95M-$99M
TipRanks · 05/13 13:22
Xtant Medical Updates Q1 Results and Raises 2026 Guidance
TipRanks · 05/13 11:33
Xtant Medical GAAP EPS of -$0.02, revenue of $20.9M, raises FY guidance
Seeking Alpha · 05/13 11:20
*Xtant Medical Holdings Raises 2026 View To Rev $101M-$105M >XTNT
Dow Jones · 05/13 11:09
Xtant Medical Raises FY2026 Sales Guidance from $95.000M-$99.000M to $101.000M-$105.000M vs $96.725M Est
Benzinga · 05/13 11:02
More
Webull provides a variety of real-time XTNT stock news. You can receive the latest news about Xtant Medical through multiple platforms. This information may help you make smarter investment decisions.
About XTNT
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.